Researchers test if extra year of kidney drug boosts protection
Disease control
Recruiting now
This study is for adults with IgA nephropathy, a kidney disease, who have already completed a standard 9-month course of the drug TARPEYO. It aims to see if continuing the treatment for another 15 months at a lower dose is safe and provides better long-term control of the disease…
Phase: PHASE4 • Sponsor: Calliditas Therapeutics AB • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC